How to buy Regulus Therapeutics stock (RGLS)

Regulus Therapeutics is a biotechnology business based in the US. Regulus Therapeutics shares (RGLS) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.59 – an increase of 0.63% over the previous week. Regulus Therapeutics employs 32 staff and has a trailing 12-month revenue of around $5 million.

Our top picks for where to buy Regulus Therapeutics stock

Buy Regulus Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Regulus Therapeutics stock price (NASDAQ: RGLS)

Use our graph to track the performance of RGLS stocks over time.

Regulus Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$1.59
52-week range	$1.08 - $3.00
50-day moving average more info button	$1.52
200-day moving average more info button	$1.89
Wall St. target price	$10.33
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.02

Is it a good time to buy Regulus Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Regulus Therapeutics price performance over time

Historical closes compared with the close of $1.59 from 2024-12-20

1 week (2024-12-13)	0.63%
1 month (2024-11-22)	8.16%
3 months (2024-09-20)	-12.64%
6 months (2024-06-21)	-36.65%

1 year (2023-12-21)	28.23%
2 years (2022-12-22)	20.45%
3 years (2021-12-21)	3.558
5 years (2019-12-20)	6.4

Regulus Therapeutics financials

Revenue TTM	$5 million
Gross profit TTM	$-18,410,000
Return on assets TTM	-42.39%
Return on equity TTM	-72.36%
Profit margin	0%
Book value	$1.33
Market Capitalization more info button	$98.9 million

TTM: trailing 12 months

Regulus Therapeutics share dividends

We're not expecting Regulus Therapeutics to pay a dividend over the next 12 months.

Have Regulus Therapeutics's shares ever split?

Regulus Therapeutics's shares were split on a 1:10 basis on 28 June 2022 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Regulus Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Regulus Therapeutics shares which in turn could have impacted Regulus Therapeutics's share price.

Regulus Therapeutics share price volatility

Over the last 12 months, Regulus Therapeutics's shares have ranged in value from as little as $1.08 up to $3. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Regulus Therapeutics's is 1.628. This would suggest that Regulus Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Regulus Therapeutics overview

Regulus Therapeutics Inc. , a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California. .

Frequently asked questions

What percentage of Regulus Therapeutics is owned by insiders or institutions?
Currently 1.689% of Regulus Therapeutics shares are held by insiders and 88.257% by institutions. How many people work for Regulus Therapeutics?
Latest data suggests 32 work at Regulus Therapeutics. When does the fiscal year end for Regulus Therapeutics?
Regulus Therapeutics's fiscal year ends in December. Where is Regulus Therapeutics based?
Regulus Therapeutics's address is: 4224 Campus Point Court, San Diego, CA, United States, 92121 What is Regulus Therapeutics's ISIN number?
Regulus Therapeutics's international securities identification number is: US75915K3095 What is Regulus Therapeutics's CUSIP number?
Regulus Therapeutics's Committee on Uniform Securities Identification Procedures number is: 75915K200